Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SPECIAL ARTICLE

Management of infectious complications associated with coronavirus infection in severe patients admitted to ICU

Á. Estella a,⁎, P. Vidal-Cortés b, A. Rodríguez c, D. Andaluz Ojeda d, I. Martín-Loeches e, E. Díaz f, B. Suberviola g, M.P. Gracia Arnillas h, M. Catalán González i, F. Álvarez-Lerma j, P. Ramírez k, X. Nuvials l, M. Borge m, R. Zaragoza n

a Servicio de Medicina Intensiva, Hospital Universitario de Jerez, Departamento de Medicina, Facultad de Medicina de Cádiz, Jerez de la Frontera, Cádiz, Spain
b Servicio de Medicina Intensiva, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
c Servicio de Medicina Intensiva, Hospital Universitario Joan XXIII de Tarragona, Tarragona, Spain
d Servicio de Medicina Intensiva, Hospital Universitario de Sanchinarro de Madrid, Madrid, Spain
e PhD JFICMI Consultant in Intensive Care Medicine, CLOD Dublin Midlands Group, St James’s University Hospital, Trinity Centre for Health Sciences, HRB-Welcome Trust St James’s Hospital, Dublin, EIRE, Universidad de Barcelona, Barcelona, Spain
f Servicio de Medicina Intensiva, Hospital Parc Taulí, Sabadell, Spain
g Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain
h Servicio de Medicina Intensiva, Hospital Universitario del Mar, Barcelona, Spain
i Servicio de Medicina Intensiva, Hospital Universitario 12 de Octubre, Madrid, Spain
j Servicio de Medicina Intensiva, Parc de Salut Mar, Hospital del Mar, Barcelona, Spain
k Servicio de Medicina Intensiva, Hospital La Fe de Valencia, Valencia, Spain
l Servicio de Medicina Intensiva, Hospital Vall d’Hebrón, Barcelona, Spain
m Unidad Multidisciplinar de Sepsis, Servicio de Medicina Intensiva, Hospital Universitario Son Llatzer, IDISBA, Enfermedades Infecciosas UIB, Palma de Mallorca, Área de Sepsis e Infecciosas, Federación Ibérica y Panamericana de Medicina Intensiva (FEPIMCTI), Palma de Mallorca, Spain
n Servicio de Medicina Intensiva, Hospital Universitario Dr. Peset, Valencia, Spain

Received 22 February 2021; accepted 17 April 2021
Available online 24 August 2021

KEYWORDS
SARS-CoV-2;
Infection prevention;

Abstract Infections have become one of the main complications of patients with severe SARS-CoV-2 pneumonia admitted in ICU. Poor immune status, frequent development of organic failure requiring invasive supportive treatments, and prolonged ICU length of stay in

⁎ Please cite this article as: Estella Á, Vidal-Cortés P, Rodríguez A, Andaluz Ojeda D, Martín-Loeches I, Díaz E, et al. Manejo de las complicaciones infecciosas asociadas con la infección por coronavirus en pacientes graves ingresados en UCI. Med Intensiva. 2021;45:485–500.

⁎ Corresponding author.
E-mail address: ltoestella@hotmail.com (Á. Estella).

2173-5727/© 2021 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.
Introduction

Over one year has gone by since the description of the first cases of respiratory infection due to the SARS-CoV-2 coronavirus. The Spanish national COVID-19/SEMICYUC registry of cases admitted to Intensive Care Units (ICUs) in Spain has evidenced a high percentage of patients who develop organ failure (100% respiratory, 44% cardiovascular and 30% renal), with long ICU stays (14 days [range 8–26]) and a mortality rate of 32.6% according to the results corresponding to the first 2200 patients published. Potere et al., in a systematic review and meta-analysis of the first series of patients in the ICU, documented a mortality rate of 34% that increased to 83% among patients on mechanical ventilation (MV) – a figure significantly higher than that observed in the COVID-19/SEMICYUC registry.

It can be affirmed that the empirical treatments with scant scientific evidence used in the early stages of the pandemic unfortunately yielded no benefits and did not modify the ominous course of the severe cases seen in the ICU. Likewise, the first data generated by the ENVIN-COVID registry, based on the analysis of 1525 patients with COVID-19 admitted to intensive care between 15 March and 30 May, showed that 50% of the patients had suffered one or more infections related to medical care, and that the frequencies of the different controlled infections had multiplied between two- and four-fold (ENVIN-COVID report, 2020). It therefore seems prudent to place emphasis on measures for the prevention of infections in the ICU, and on their early detection, with the aim of providing adequate and early treatment in the difficult challenge of combating the high associated mortality.

With this aim in mind, the Working Group on Infectious Diseases and Sepsis (Grupo de Trabajo de Enfermedades Infecciosas y Sepsis [GTEIS]) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias [SEMICYUC]), on occasion of its latest ordinary meeting, agreed to carry out a literature review on the state of the art and offer a series of treatment recommendations established by the authors of this document, which were selected by the coordinators of the Working Group on the basis of their experience in infectious diseases.

Role of immune modulating treatments in nosocomial infection

During the first months of the pandemic, the lowering of a dysregulated immune response was considered to be a potential therapeutic strategy. As a result, and even in the absence of clear scientific evidence, frequent use was made of a range of antiinflammatory drugs and immune modulators such as glucocorticoids, inhibitors of interleukins and/or their receptors, antimalarial, antimitotic agents, calcineurin inhibitors, etc. However, these drugs are not without side effects – one of the most serious of which is...
an enhanced susceptibility to superinfections in the hospital setting.

Knowledge about the effect of corticosteroids upon the development of superinfections in patients with SARS-CoV-2 infection is presently limited. A meta-analysis of the clinical trials that have evaluated corticosteroid use in critical patients with SARS-CoV-2 infection carried out by the World Health Organization (WHO) concluded that the included studies contributed little information on the adverse effects, and that no meta-analysis of the data was possible. Nevertheless, some studies suggested that the use of corticosteroids may be associated with an increased risk of certain infections such as bacteremias, particularly when these drugs are combined with other immunosuppressors.

Based on the evidence available at the time of drafting this document, and following the guidelines of the WHO, among others, the use of corticosteroids – preferably dexamethasone – is recommended for the treatment of patients with severe COVID-19. It should be considered that although patients with milder respiratory failure could benefit from such treatment, the maximum benefits have been observed in critical patients subjected to mechanical ventilation (odds ratio [OR] 0.66 [95% CI: 0.53–0.82]). Monedero et al. reported that the early administration of corticosteroids, within the first 48 h of admission to the ICU is associated to a lesser risk of nosocomial infection (56.3% of cases; OR 1.39, p = 0.05) than when such treatment is provided on a later basis (69.9% of cases; OR = 2.5 p < 0.001) – though the risk of infection is even lower among those patients who never received the drug (48.2% of the cases, OR = 1). Table 1 summarizes the main studies on the use of corticosteroids and their association to the development of infections. As regards the type of drug and dose, dexamethasone is preferentially advised, at a dose of 6–7.5 mg/day between 7 and 10 days, since it is the drug substance used in a larger number of studies and which has been found to afford statistically significant clinical benefits.

Tocilizumab

The use of tocilizumab could be justified to reduce the inflammatory component associated with COVID-19, though as a deleterious effect, the drug could interfere with the host immune response to viral replication. Its prescription in this disease condition is therefore controversial, with evidence both in favor and against its use. The main side effect of tocilizumab is a predisposition to develop infections. Data obtained from post-authorization experience with the drug indicate that the most frequent complication is upper airway infections, including pneumonia (>10% of the patients), followed by cellulitis and herpetic reactivations (1–10%) and, more rarely, diverticulitis (<1%).

Between 3–7% of all patients may develop a potentially serious infection. In the context of COVID-19, a recent study published by Somers et al. evidenced that the administration of tocilizumab in a cohort of 154 patients subjected to mechanical ventilation was associated to a greater proportion of superinfections (54% versus 26%; p < 0.001). Pneumonia (45%) and bacteremia (14%) were the most frequent conditions, and the most commonly isolated organism was Staphylococcus aureus (S. aureus) (51% of the cases) – though no differences were observed in the 28-day mortality rate between those patients treated with tocilizumab with or without superinfection [22% versus 15%; p = 0.42]. However, most of the studies have recorded no higher incidence of infection in those patients who received the drug. In the largest meta-analysis to date, Tleyjeh et al., comprising a total 9850 patients, found the use of tocilizumab to imply no higher nosocomial infection rate than that recorded in the control group, though the drug was associated to a lesser mortality rate and/or need for mechanical ventilation. In the largest clinical trial to date – the RECOVERY study – a decrease in mortality was observed (relative risk [RR] 0.86 [95% CI: 0.77–0.96]; p = 0.006) in the subgroup of patients that received tocilizumab, with C-reactive protein >75 and pulsioximetry <92%. Of note is the fact that 82% of the patients received corticosteroids in both arms of the study, and no data were moreover provided on the incidence of nosocomial infection. Table 2 summarizes the main studies on tocilizumab and its association to the appearance of infections.

Lastly, it must be remembered that tocilizumab inhibits the acute phase reactants produced in the liver, such as C-reactive protein, which therefore limits their usefulness in the diagnosis and assessment of treatment response in patients with nosocomial infection and sepsis.

Prevention of infections related to medical care

The adoption of the recommendations of the Zero Projects has proven to be effective in reducing the appearance of infections related to medical care during patient admission to the ICU in Spain. The statistics on the different infections related to the use of invasive devices published by the ENVIN registry in the year 2019 were more than adequately compliant with the quality standards of the SEMICYUC. During the early phases of the COVID-19 pandemic, the application of contingency plans designed to address the growing healthcare demands, implied the introduction of important structural, functional and human changes that posed barriers for complying with the established prevention measures. In recent months, important increments have been reported in the incidence of infections related to medical care among the COVID-19 patients admitted to different Spanish ICUs. The Critical Patients Safety Projects Advisory Council has recently published a document proposing adaptation of the recommendations of the Zero Projects during the SARS-CoV-2 pandemic. Appendix B summarizes the measures contemplated in the mentioned document, and which are complemented by adaptation of the management of invasive devices during patient transfer or during placement in prone decubitus, the prevention of pressure ulcers, and the application of body hygiene.

Bacterial coinfection

Despite the recording of a low incidence of bacterial coinfection in hospitalized patients with SARS-CoV-2, the incidence recorded in the ICU according to the COVID-19/SEMICYUC registry was 9.3%. The recommendation
| Study reference and design | Patients | Intervention | Comparison | Results | Superinfection rate |
|---------------------------|----------|--------------|------------|---------|--------------------|
| Recovery8 RCT             | 2104     | DXM 6 mg/day × 10 d + DXM 10 mg/day × 5 d MPD 0.5 mg/kg/12 h × 5 d | Standard treatment | 2.8% overall mortality (OR 0.83) 12.1% mortality on MV (OR 0.64) | Corticosteroids 21.9% versus ST 29.1% standard Bacteremia 7.9% corticosteroids versus 9.5% in ST No differences in incidence of sepsis, bacteremia or viral clearance (PCR+) on day 7 |
| CoDex10 RCT               | 299      | DXM 20 mg/day × 5 d + DXM 10 mg/day × 5 d | Standard treatment | 2.4% mortality or need for MV |
| Metcord11 RCT             | 416      | Placebo MPD 20 mg/12 h/day × 3 d | Placebo | NS |
| CAPE COVID12 RCT          | 149      | HCT 200 mg/day × 7 d and decreasing dose × 7 d (14 d) | Placebo | NS |
| REMAP-CAP13 RCT           | 384      | HCT 50 mg/6 h × 7 d or 100 mg/6 h × 7 d MPD 250 mg/day × 3 d | Standard treatment | 93% and 80% probability of superiority in need of organ support |
| Edalatifard et al.14 RCT  | 68       | Placebo MPD 20 mg/12 h × 3 d | Placebo | NS |
| Glucocovid15 RCT          | 85       | MPD 40 mg/12 h × 3 d and MPD 20 mg/12 h × 3 d | Standard treatment | 24% composite variable (death, admission to ICU or need for MV) |
| Kim et al.16 Meta-analysis| 49,569   | Various regimens | Standard treatment | OR 0.78 (0.66–0.91) overall mortality OR 0.54 (0.40–0.73) mortality patients ICU OR 0.72 (0.57–0.87) for mortality OR 0.64 (0.50–0.82) for use of MV Greater incidence of infections and sepsis |
| Van Paassen et al.17 Meta-analysis | 20,197 | Various regimens | Standard treatment | OR 0.66 (0.53–0.82) for mortality OR 0.64 (0.50–0.82) for DXM OR 0.69 (0.43–1.12) for HCT |
| OMS18 Meta-analysis       | 1703     | Various regimens | Standard treatment | OR 0.69 (0.29–2.87) for MPD RR 0.89 (0.82–0.96) for mortality RR 0.85 (0.72–1.00) for mortality in ventilated patients |
| Pasin et al.19 Meta-analysis | 7692   | Various regimens | Standard treatment | OR 0.72 (0.66–0.80) overall mortality OR 0.54 (0.40–0.73) mortality patients ICU OR 0.72 (0.57–0.87) for mortality OR 0.64 (0.50–0.82) for use of MV Greater incidence of infections and sepsis |

d: days; DXM: dexamethasone; RCT: randomized clinical trial; HCT: hydrocortisone; INS: insufficient information; MPD: methylprednisolone; NA: no data available; NS: nonsignificant; OR: odds ratio; P: placebo; RR: relative risk; MV: mechanical ventilation.
| Study reference and design | Patients | Intervention | Comparison | Results | Superinfection rate |
|---------------------------|----------|--------------|------------|---------|---------------------|
| Salama et al.\(^{25}\), EMPACTA, RCT Rosas et al.\(^{26}\), COVACTA, RCT | 377 | TCZ (8 mg/kg, max. 800 mg, 1−2 doses) TCZ (8 mg/kg, max. 800 mg, 1−2 doses) | Placebo | MV/ECMO/mortality 28 d: 19.3% TCZ, versus: 12% P, \( p = 0.004 \) Mortality: NSHospital stay. TCZ: 20. P: 28 d (\( p = 0.037 \)) Admission ICU. TCZ: 23.6%, SC: 40.6% (\( p = 0.01 \)) ICU stay. TCZ: 9.8, SC: 15.5 d (\( p = 0.045 \)) | TCZ 10% versus P 12.6% TCZ 21% versus P 25.9% |
| Stone et al.\(^{27}\), BACC Bay Tocilizumab, RCT | 242 | TCZ (8 mg/kg, max. 800 mg, one dose) | Placebo | NS | TCZ 8.15 versus P 17.1% |
| Salvarani et al.\(^{28}\), RCT-TCZ-COVID, RCT | 123 | TCZ (8 mg/kg, max. 800 mg, 1−2 doses) | Standard treatment | NS | TCZ 1.7% versus ST 6.3% |
| Hermine et al.\(^{29}\), CORIMUNO-19, RCT | 131 | TCZ (8 mg/kg, max. 800 mg, 1−2 doses) | Standard treatment | NS | TCZ 3.2% versus ST 16.4% |
| Horby et al.\(^{30}\), RECOVERY, RCT | 4166 | TCZ (various regimens) | Standard treatment (includes corticosteroids) | Mortality 28 d: TCZ: RR 0.86 (95%CI 0.77—0.96, \( p = 0.006 \)) | NA |
| Gordon et al.\(^{31}\), REMAP-CAP RCT | 826 | TCZ (8 mg/kg, max. 800 mg, 1−2 doses)\( n = 366 \) Sarilumab (400 mg) \( n = 48 \) | Standard treatment | Days without ventilation and/or hemodynamic support on day 21: TCZ: 10, sarilumab: 11, ST: 0Hospital mortality: TCZ: 28%, sarilumab: 22.2% ST: 35.8% | TCZ 0.2% versus ST 0% |
| Veiga et al.\(^{32}\), TOCIBRAS, RCT | 129 | TCZ (8 mg/kg, max. 800 mg) | Standard treatment | Early interruption due to increased mortality in patients treated with tocilizumab | PB 15% versus ST 16% |
| Tleyjeh et al.\(^{24}\), Meta-analysis | 9850 | TCZ (various regimens) | Standard treatment | Mortality. TCZ: OR 0.58 (0.51—0.66) TCZ: RR 0.63 (0.38—1.06) | |
Table 2 (Continued)

| Study reference and design | Patients | Intervention | Comparison | Results | Superinfection rate |
|----------------------------|----------|--------------|------------|---------|---------------------|
| Gupta et al.\(^{33}\), STOP-COVID, OS | 3491 | TCZ (doses not specified) | Standard treatment | Hospital mortality. TCZ: HR 0.71 (95%CI, 0.56–0.92) |
| | | | | Mortality. TCZ HR: 0.54 (95%CI, 0.35–0.84) | TCZ 32.3% versus ST 31.1% |
| Somers et al.\(^{23}\), OS | 154 | TCZ (8 mg/kg, max. 800 mg) | Standard treatment | TCZ: HR 0.71 (95%CI, 0.56–0.92) |
| Fisher et al.\(^{34}\), OS | 115 | TCZ (400 mg) | Standard treatment | 30-day mortality. TCZ: OR 1.04 (95%CI, 0.27–3.75) |
| Biran et al.\(^{35}\), OS | 764 | TCZ (400 mg, 1–2 doses) | Standard treatment | Hospital mortality. TCZ: HR: 0.64 (95%CI 95% 0.47–0.87, p = 0.004) |
| Guaraldi et al.\(^{36}\), TESEO, OS | 544 | TCZ (8 mg/kg, max800 mg, 2 doses) (n = 179) | Standard treatment | Death/mechanical ventilation. TCZ: HR 0.61 (95%CI, 0.4–0.92), p = 0.020 |
| Rosotti et al.\(^{37}\), OS | 222 | TCZ (8 mg/kg, max800 mg, 1–2 doses) (n = 74) | Standard treatment | Survival: TCZ: HR: 2.004 (1.05–3.81) Survival in ICU: HR: 30.055 (95%CI 1.42–636.28) |
| Rojas-Martee et al.\(^{38}\), OS | 193 | TCZ Regimen not specified | Standard treatment | Mortality: TCZ: 52%, SC: 62%, p = 0.09; Mortality in non-ventilated patients: TCZ: 6.1%, SC: 26.5%, p = 0.024 |
| | | | | Bacteremia: TCZ 12.5% versus ST 23.7%; Fungemia: TCZ 4.2% versus ST Fungemia 3.1% |

\(^{d}\): days; RCT: randomized clinical trial; ECMO: extracorporeal membrane oxygenation; OS: observational study; INS: insufficient information; NA: no data available; NS: nonsignificant; OR: odds ratio; P: placebo; RR: relative risk; TCZ: tocilizumab; MV: mechanical ventilation; NIV: noninvasive ventilation.
Table 3  Reported incidence of infectious complications in series of patients with severe SARS-CoV-2 pneumonia.

| Series                  | No. patients ICU | Type of study                      | Infection | Incidence/prevalence | Microbiology               |
|-------------------------|------------------|------------------------------------|-----------|----------------------|---------------------------|
| ENVIN-COVID⁵             | n = 1525         | Retrospective observational Multicenter (n = 54) | no. infections/total patients: 62.75% infections/1000 days stay: 19.5 VAP (n = 332) CRB (n = 169) C-UTI (n = 181) | VAP no. VAP/1000 days MV: 14.31%no. VAP/1000 days of stay: 22.16%no. VAP/1000 days device: 10.43%PB no. PB/1000 days: 12.42%no. PB/100 patients: 24.20%no. PB 1000 days stay: 10.24%CRB no. CRB/1000 days device: 6.32% C-UTI no. UTI/1000 days of BC: 6.54%no. UTI/100 patients: 18.87%no. UTI/1000 days stay: 5.58% | VAP: *P. aeruginosa* 32.52% S. *aureus* 10.33% K. *pneumoniae* 8.51%PB/CRB S. *epidermidis* 29.41% E. *faecalis* 19.12% E. *faecium* 8.53% C. *abicans* 7.06% C-UTI E. *faecalis* 21.16% C. *abicans* 13.23% E. *faecium* 12.70% P. *aeruginosa* 12.17% E. *coli* 11.11% Not described |
| Soriano et al. ⁴⁴       | n = 83           | Retrospective observational (1 center) | no. infections/total patients: 131.32% infections/1000 days stay: 59.61% | VAP no. VAP/total of patients: 42.16%no. VAP/total of days: 18.19%PB/CRB no. PB/100 patients: 33.73%no. PB/1000 days stay: 15.1%no. CRB/1000 patients: 8.43%no. CRB/1000 days stay: 3.71%C-UTI no. UTI/100 patients: 38.55%no. UTI/1000 days stay: 17.18% | Respiratory infection A. *baumannii* 33.3% P. *aeruginosa* 25.63%Other grammegative bacilli 20.51 S. *aureus* 12.82%CRB CNS 87.5% S. *aureus* 6.25% A. *baumannii* 6.25% C-UTI E. *faecalis* 30.18% E. *faecalis* 24.52% E. *coli* 11.32% Candida spp. 11.32% |
| Nebreda-Mayoral et al.⁴⁵ | n = 50           | Retrospective observational (1 center) Cohort of 113 hospitalized patients with 50 admitted to ICU | no. infections/total patients: 204% | patients with respiratory infection × 100: 64%patients with CRB × 100: 20%patients with UTI × 100: 60% | Respiratory infection A. *baumannii* 33.3% P. *aeruginosa* 25.63%Other grammegative bacilli 20.51 S. *aureus* 12.82%CRB CNS 87.5% S. *aureus* 6.25% A. *baumannii* 6.25% C-UTI E. *faecalis* 30.18% E. *faecalis* 24.52% E. *coli* 11.32% Candida spp. 11.32% |
| Series         | No. patients | Type of study                                                                                                                                                                                                 | Infection                                                                 | Incidence/prevalence                                                                 | Microbiology                                                                 |
|---------------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Ramirez et al. | n = 44       | Retrospective observational. Patients with COVID-19                                                                                                                                                    | Nosocomial infection in 29.5% of the patients                               | VAP in 23.5% of the patients TAV in 2.9% of the patients CRB in 6.8% of the patients | *P. aeruginosa* 46.7% *S. aureus* (20%) *E. coli* 6.7% *S. anginosus* (n = 3) *P. aeruginosa* (n = 3) *S. aureus* (n = 2) *E. coli* (n = 1) *S. oralis* (n = 1) *K. pneumoniae* (n = 1) *E. faecalis* (n = 1) |
| Rodriguez et al. | n = 44       | Prospective observational (1 center)                                                                                                                                                                        | Nosocomial infection in 29.5% of the patients                               | VAP in the 30.2% of the patients TAV in 2.9% of the patients CRB in 6.8% of the patients | *P. aeruginosa* 46.7% *S. aureus* (20%) *E. coli* 6.7% *S. anginosus* (n = 3) *P. aeruginosa* (n = 3) *S. aureus* (n = 2) *E. coli* (n = 1) *S. oralis* (n = 1) *K. pneumoniae* (n = 1) *E. faecalis* (n = 1) |
| Bardi et al.   | N = 140      | Prospective observational (1 center)                                                                                                                                                                        | Nosocomial infection in 40.7% of the patients91 nosocomial infection episodes in 57 patients | PB 31%CRB 25%VAP 23%HAP/TB 10%UTI 8%                                                  | *P. aeruginosa* 38% *MRSA* 24% *A. fumigatus* 9% *S. maltophilia* 9%HAP/TB *P. aeruginosa* 33% *MRSA* 21% *A. fumigatus* 9% *H. influenza* 9% *MSSA* 9% *S. maltophilia* 9%UTI *E. faecalis* 44% *E. faecium* 28% *P. aeruginosa* 14% *A. baumannii* 14% |

PB: primary bacteremia; CRB: catheter-related bacteremia; C-UTI: bladder catheter-related urinary tract infection; HAP: hospital-acquired pneumonia; VAP: ventilator-associated pneumonia; MSSA: methicillin-sensitive *S. aureus*; MRSA: methicillin-resistant *S. aureus*; CNS: coagulase-negative *Staphylococcus*; BC: bladder catheter; TB: tracheobronchitis.
Table 4  Microbiological study of respiratory samples.

| Gram staining and microbiological culture | Determination of presence of coronavirus | PCR testing for virus influenza and RSV | KOH and/or calcofluor staining | Real-time PCR testing for Aspergillus* | LFA*/Galactomannan antigen | Staining and culture for mycobacteria |
|------------------------------------------|----------------------------------------|----------------------------------------|--------------------------------|--------------------------------------|-----------------------------|---------------------------------------|
| LFA: lateral flow assay.                 |                                        |                                        |                               |                                      |                             | * According to availability at the center. |

not. What is clear is that the potential presence of bacterial coinfection should be investigated in all cases. A strategy which in our opinion seems reasonable is to start antibiotic treatment considering the most frequent pathogens in community-acquired pneumonia, and to adjust or suspend treatment after 48–72 h conditioned to the microbiological results obtained. If empirical antibiotic therapy is started, we recommend combination treatment in the form of a third-generation cephalosporin such as ceftriaxone or cefotaxime associated to levofloxacin or azithromycin, though a fifth-generation cephalosporin such as ceftaroline could also be prescribed.

Table 4  Microbiological study of respiratory samples.

| Gram staining and microbiological culture | Determination of presence of coronavirus | PCR testing for virus influenza and RSV | KOH and/or calcofluor staining | Real-time PCR testing for Aspergillus* | LFA*/Galactomannan antigen | Staining and culture for mycobacteria |
|------------------------------------------|----------------------------------------|----------------------------------------|--------------------------------|--------------------------------------|-----------------------------|---------------------------------------|
| LFA: lateral flow assay.                 |                                        |                                        |                               |                                      |                             | * According to availability at the center. |

Ventilator-associated respiratory infection

Ventilator-associated respiratory infection (VARI), including ventilator-associated tracheobronchitis and ventilator-associated pneumonia (VAP), are common in critical patients subjected to mechanical ventilation. Patients with pneumonia due to SARS-CoV-2 could be at an increased risk of VARI, due to acute respiratory distress syndrome (ARDS) and the long duration of mechanical ventilation. Acute respiratory distress syndrome is a well-known risk factor for VAP, and its incidence in ventilated patients with SARS-CoV-2 pneumonia is reportedly high (42–89%). Likewise, SARS-CoV-2 is responsible for alterations of host immune response.

Recently, two Spanish groups have published their experience, with an incidence of almost 52% referred to infections acquired in the ICU — respiratory foci being the most common presentation in both series, and implying significantly higher mortality in one of the studies. Pseudomonas aeruginosa was the most frequently isolated microorganism.

Rouze et al. carried out a multicenter study to determine the relationship between SARS-CoV-2 infection and the incidence and etiology of VARI. The study was carried out in 36 ICUs in Europe (28 in France, 3 in Spain, 3 in Greece, 1 in Portugal and 1 in Ireland). The interesting feature of this study is that it included the same number of patients on mechanical ventilation per center with SARS-CoV-2 infection, influenza infection or no viral infection. The main finding was that the incidence of ventilator-associated tracheobronchitis and VAP was greater in the patients with SARS-CoV-2 than in the other two groups (influenza infection or no viral infection). Gramnegative bacilli were responsible for most of the first VARI episodes in all three study groups. P. aeruginosa, Enterobacter spp. and Klebsiella spp. were the most commonly identified bacteria. The percentage of patients with VARI involving multidrug-resistant bacteria was lower in pneumonia due to SARS-CoV-2 than in the other two groups.

The choice of empirical and/or guided treatment should be based on the clinical entity and the severity of presentation, the presence of risk factors for infection due to a multidrug-resistant microorganism, the existence of comorbidities, and knowledge of the local flora and multidrug-resistance rates of the center involved, according to the proposed algorithm. The increase in bacterial resistances and the high incidence of infections involving gramnegative bacilli such as Klebsiella spp. and Pseudomonas spp., lead us...
to consider empirical treatments with activity against this etiological profile, including carbapenems (for which the appearance of resistances is increasing), ceftazidime-avibactam and ceftolozane-tazobactam, whose spectrum of action covers these possibilities. The duration of treatment has not been clearly established, and in this type of infection in particular, the decision must be individualized, in view of the important lung damage caused. Likewise, we always must consider the possibility of shortening both the duration of treatment and tapering of the regimen, based on the use of scales such as the Clinical Pulmonary Infection Score (CPIS), and biomarkers such as C-reactive protein and particularly procalcitonin in combination may be of help.

Table 5 summarizes the recommendations on the management of VAP in patients with COVID-19.

### Table 5  Recommendations for the management of ventilator-associated respiratory infections in critical patients with SARS-CoV-2 pneumonia.

| Recommendation |
|----------------|
| - Due to their high incidence, a strong level of suspicion should be maintained, with the early start of antibiotic treatments. |
| - Empirical and/or guided treatment should be based on the clinical entity and the severity of presentation, the presence of risk factors for infection due to a multiresistant microorganism, the existence of comorbidities, the possible use of rapid techniques, and knowledge of the local flora and multiresistance rates of the center. |
| - Initial empirical combination coverage should be provided with antipseudomonal betalactams, including ceftazidime–avibactam or ceftolozane–tazobactam plus quinolones or aminoglycosides. |
| - Empirical coverage of MRSA is not necessary if its incidence in the center is low or inexistent. |
| - In order to avoid unwarranted antibiotic use, treatment should be suspended if infection is not documented. |
| - In guided treatment, monotherapy is advised, with the possibility of reducing the spectrum of action. |
| - The duration of treatment should be individualized, and longer therapy may be necessary in these patients, depending on the clinical course, biomarkers use and the presence of multiresistances. |

### Catheter-related bacteremia

The Bacteremia Zero Project has reduced the incidence of catheter-related bacteremia (CRB), though in the moments of maximum critical care bed occupation and expansion it has been difficult to maintain compliance with the measures recommended by this and by other similar projects in our Units. A greater incidence of nosocomial bacteremia has been observed in COVID-19 patients admitted to hospital than in non-COVID-19 patients (5.3% versus 1.4%; p < 0.001), and admission to the ICU has moreover been identified as a risk factor. The ENVIN-COVID report of 2020 has described an incidence of 6.32 cases per 1000 days of central venous catheter, which is much higher than usual in our Units. Similar and even poorer results have been obtained in other studies. Giacobbe et al. documented an incidence of nosocomial bacteremia of 47 episodes per 1000 patients-day, with 73% corresponding to primary bacteremias and CRB. In contrast, Buetti et al., in their case-CONTROL study, found that COVID-19 patients have no greater risk of CRB than non-COVID-19 patients. Both studies do coincide in describing a greater risk of CRB in patients treated with corticosteroids, tocilizumab or anakinra – observations that could not be confirmed in the clinical trials with these drugs.

The situations in which CRB should be suspected, and the required diagnostic procedures, are no different from those referred to non-COVID-19 patients. With regard to management, there is no evidence to establish treatment regimens different from the usual ones – though some aspects need to be considered. In relation to the choice of antimicrobial therapy and catheter withdrawal, patients treated with corticosteroids or tocilizumab are to be regarded as immunosuppressed individuals, at least during treatment with corticosteroids and between two and four weeks after the administration of tocilizumab. We should adapt the antimicrobial treatment to the local resistances profile, focusing special attention on the changes in microbiology that might appear derived from the peculiarities of COVID-19 patients (Table 3), the high frequency of treatment with cephalosporins upon admission, and care of critical patients in areas different from the usual areas.

### Device-related urinary tract infection

According to the data of the ENVIN-HELICS report of the year 2020, which describe the analysis of 1525 patients with SARS-CoV-2 pneumonia in the first wave of the pandemic, 19% of the infections related to medical care corresponded to bladder catheter-related urinary tract infections (C-UTI), with an incidence of 6.54 C-UTI episodes per 1000 days of catheter. A series of factors may predispose to the development of C-UTI, particularly a prolonged ICU stay, immune alterations, the need for an indwelling bladder catheter, and antibiotic treatment. The strategy for the prevention of C-UTI in the ICU has been extensively developed in the UTI-ZERO Project, and there are no differential aspects applicable to patients with SARS-CoV-2 infection. The most frequently isolated organism has been *Enterococcus faecalis* (Table 3). The change in microbiology observed in C-UTI in patients with SARS-CoV-2 pneumonia must be interpreted with caution, since it may be explained by the initial management approach involving cephalosporins, which since then has changed. Accordingly, until new data are forthcoming, the antibiotic treatment of these patients should ensure the coverage of gramnegative bacilli, considering the significant percentage of *P. aeruginosa* isolates. Antifungal treatment can be provided by fluconazole in patients with symptomatic candiduria and in those with asymptomatic candiduria and a risk of disseminated disease, as in neutropenic individuals, immunosuppressed patients or patients subjected to urological manipulations. In the case of infection due to *Candida*...
**krusei or Candida glabrata** resistant to azoles, use can be made of amphotericin B deoxycholate via the intravenous route. The echinocandins have been shown to be effective in some cases despite their scant elimination in urine. The current tendency in relation to the duration of treatment is to prescribe short cycles of between 3–7 days.\(^{71,72}\)

### Opportunistic infections with special emphasis on invasive fungal infection

In its more severe presentations, pneumonia due to SARS-CoV-2 has been associated with an increase in the incidence of opportunistic infections. Although a prolonged ICU stay or treatments with corticosteroids and/or immune modulators can be identified as risk factors in these patients, there is growing evidence that infection due to this virus and the development of ARDS give rise to lymphocyte dysfunction,\(^{73}\) which in turn can favor the development of opportunistic infections. We will focus on the two most common opportunistic infections in patients with COVID-19: invasive pulmonary aspergillosis and the reactivation of Herpesvirus*dae*. A marked increase in Candida spp. isolates has been observed, though the treatment in such cases is no different from that indicated in patients without SARS-CoV-2 infection.

### Pulmonary aspergillosis associated to SARS-CoV-2 infection

Pulmonary aspergillosis is a feared complication, due to its high associated mortality rate in critical patients subjected to mechanical ventilation. On occasion of the influenza A H1N1 pandemic in 2009, a number of authors had described an increase in the incidence of pulmonary aspergillosis among patients that developed ARDS.\(^{74}\) This same situation has been documented in patients with severe pneumonia due to SARS-CoV-2\(^{79,80}\), the latter condition therefore must be included as a risk factor, in which active assessment of aspergillosis is advised.

Clinical and radiological criteria may be of help in diagnosing this complication, though they lack the necessary specificity to establish the diagnosis on their own.\(^{77,78}\) The difficulties in detecting pulmonary aspergillosis has led to urgency in establishing specific diagnostic recommendations for patients with SARS-CoV-2,\(^ {79,80}\) In this respect, and as a first measure, these patients should be considered to be at risk, and an active assessment of Aspergillus should be made, with the obtainment of respiratory samples – since the determination of galactomannan in the serum of non-neutropenic patients offers only low sensitivity. Sampling preferably should be invasive in the form of fiber bronchoscopy in order to better differentiate between colonization and infection. The microbiology laboratory should perform staining with calcofluor and/or KOH in search of the presence of fungal elements in the direct sample, with the quantitative determination of galactomannan, and culture. The SARS-CoV-2 pandemic is generating an important work burden, and the quantification of galactomannan antigen is not available every day of the week. Furthermore, the results referred to fungal growth in culture may take some time, and we therefore need to consider the use of other faster techniques with adequate sensitivity such as lateral flow assay (LFA), which provides clinicians with very valuable information for the early start of antifungal treatment.\(^ {81}\) Other diagnostic procedures such as determination of the fungus using polymerase chain reaction (PCR) techniques, mass spectrometry or urine antigen determination are currently not available in most laboratories, though in future they undoubtedly can make a valuable contribution to the diagnosis of the disease.\(^ {82}\)

**Table 6** Recommendations for the management of pulmonary aspergillosis in critical patients with SARS-CoV-2 pneumonia.

| 1. Consider all patients with severe SARS-CoV-2 pneumonia to be at risk of suffering pulmonary aspergillosis |
| 2. Conduct active assessment of aspergillosis, collecting preferably invasive respiratory samples via fiber bronchoscopy |
| 3. Evaluate the presence of the following diagnostic criteria, and if they are confirmed, start early antifungal treatment: |
| - Clinical criteria: fever and/or worsening of respiratory function determined by the PaO\(_2\)/FiO\(_2\) ratio, and not attributable to other causes |
| - Radiological criteria: presence of a infiltrates on the plain chest radiographs |
| - Microbiological criteria (any of which justify the start of treatment): |
| Detection of galactomannan levels in respiratory sample >0.5 |
| Positive real-time PCR testing/lateral flow assay (LFA)* |
| Direct visualization of fungal elements, hyphae, in the respiratory sample (calcofluor stain) |
| Growth of *Aspergillus* spp. in culture |

* According to availability at the center.
start of treatment, and in this regard it is essential to recognize SARS-CoV-2 as representing a risk scenario where early and active assessment of this infectious complication is needed.

Reactivation of Herpesviridae in critical patients with COVID-19

The Herpesviridae family comprises several viruses, of which herpes simplex virus (HSV) and cytomegalovirus (CMV) will be addressed in this review. These viruses can remain in a latent state after primary infection, and can reactivate at a later stage if the conditions become favorable. The possibility of HSV or CMV systemic infection or infection confined to a given organ in the immune competent critical patient is the subject of intense debate. Some authors consider that the detection (using quantitative or qualitative PCR) of the presence of the virus should not be regarded as an indication of treatment, since not all studies have demonstrated benefits of such treatment in terms of patient mortality. Nonetheless, a recent meta-analysis has concluded that treatment with acyclovir reduces in-hospital mortality and mortality at 30 days. Factors such as a high number of viral copies, a lack of response to antibiotic treatment, or the presence of positive cytological data in the bronchoalveolar lavage (BAL) support the existence of pneumonia due to HSV and thus the start of treatment.

In the case of COVID-19 patients, there is growing evidence of a high frequency of reactivation of HSV and CMV. Here again, interpretation of the results may prove complex. Nevertheless, given the relative immunosuppression state caused by the lymphopenia and medication use, and the publication of clinical cases that historically demonstrate deep tissue involvement, early therapy should be considered.

The microbiological diagnosis, preferably based on quantitative PCR testing, should be considered in all patients with respiratory worsening and/or an infectious process – particularly when a bacterial origin is ruled out or the patient fails to respond to antibiotic treatment. Invasive sampling is advised (BAL or minilavage). The serological study of HSV and CMV and the quantification of CMV in plasma may be of help in evaluating the case.

The treatment of HSV infection is based on acyclovir. Gancyclovir is the drug of choice for CMV, though the presence of resistances or a lack of response may require the use of foscarnet.

Final considerations

The main limitation of this document is that the recommendations made are not fundamentally upon any analysis of the evidence, since at this time there is still much to be learned about how the pandemic should be managed, and very few studies with an adequate methodological design have been able to contribute solid information in this respect. The existing evidence therefore must be classified as being of low level. Nevertheless, it can be concluded that the scarce evidence on effective treatments applicable to SARS-CoV-2 viral infection in critical patients focuses on supportive measures, the prevention of infections related to medical care, and the early detection and treatment of those infectious complications that have been described as being common in these patients.

Authors/collaborators

All the authors form part of the GTEIS of the SEMICYUC, and were selected by its coordinators for development of the present document.

They have participated in the preparation of all the document sections and have approved the final version. AE and RZ coordinated the project that gave rise to this document.

Conflicts of interest

AE have participated in speeches/training activities organized by Pfizer, Gilead, MSD.

PVC has participated in speeches/training activities organized by Pfizer, Shionogi, MSD.

RZ has participated in speeches/training activities organized by Pfizer, Shionogi, MSD, Gilead.

The rest of the authors declare that they have no conflicts of interest.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.medin.2021.04.007.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33, http://dx.doi.org/10.1056/NEJMoa2001017.

2. Rodríguez A, Ruiz-Botella M, Martín-Loeches I, Jiménez Herrera M, Solé-Violan J, Gómez J, et al. COVID-19 SEMICYUC Working Group. Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain. Crit Care. 2021;25:63, http://dx.doi.org/10.1186/s13054-021-03487-8. PMID: 33588914; PMCID: PMC7883885.

3. Potere N, Valeriani E, Candeloro M, Tana M, Porreca E, Abbate A, et al. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care. 2020;24:389, http://dx.doi.org/10.1186/s13054-020-03022-1.

4. Estella Ā, Garnacho-Montero J. From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic. Med Intensiva. 2020;44:509–12, http://dx.doi.org/10.1016/j.medint.2020.04.009. Spanish.

5. Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). Grupo de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS). Estudio Nacional de Vigilancia de Infección Nosocomial. ENVIN-COVID: 2020. Available from: https://hws.vhebron.net/envin-helics/ [Accessed 13 April 2021].

6. Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between admin-
istration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–41.

7. Giacobbe DR, Battaglini D, Ball L, Brunetti I, Bruzzzone B, Codda G, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Invest. 2020;50:e13319. http://dx.doi.org/10.1111/eji.13319. Epub 2020 Aug 11. PMID: 32535894; PMCID: PMC7321343.

8. Horby P, Lim WS, Emberson JR, Mathers M, Bell JL, Linsell L, et al. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704. http://dx.doi.org/10.1056/NEJMoa2021436. Epub 2020 Jul 17. PMID: 32678530; PMCID: PMC7383595.

9. Monedero P, Gue A, Castro P, Candela-Toha AM, Hernández-Sanz ML, Arruti E, COVID-19 Spanish ICU Network, et al. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study. Crit Care. 2021;25:2. http://dx.doi.org/10.1186/s13054-020-03422-3. PMID: 33979463; PMCID: PMC7780210.

10. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, COALITION COVID-19 Brazil III Investigators, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324:1307–16. http://dx.doi.org/10.1001/jama.2020.1702. PMID: 32876695; PMCID: PMC7489411.

11. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, for the Metcovid Team, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2020;ciaa1777. http://dx.doi.org/10.1093/cid/ciaa1777. Epub ahead of print. PMID: 32785710; PMCID: PMC7454320.

12. Dequin PF, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, CAPE COVID Trial Group and the CRICS-TrIGGER-SepNet Network, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1298–306. http://dx.doi.org/10.1001/jama.2020.16761. PMID: 32876689; PMCID: PMC7489432.

13. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;(1317–1329).

14. Edalatifar M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56;2002088.

15. Corral-gudino L, Bahamonde A, Amaiz-revillas F, Gómez-barquero J. GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. MedRxiv. 2020;(1–24).

16. Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: a systematic review and network meta-analysis. PLoS Med. 2020;17:e1003501.

17. van Paassen J, van L, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020;24:696. http://dx.doi.org/10.1186/s13054-020-03400-9. PMID: 33317589; PMCID: PMC7735177.

18. WHO, Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–41.

19. Pasin L, Navalesi P, Zangrillo A, Kuzovlev A, Likhvantsev V, Hajjar LA, et al. Corticosteroids for patients with coronavirus disease 2019 (COVID-19) with different disease severity: a meta-analysis of randomized clinical trials. J Cardiothorac Vasc Anesth. 2021;35:578–84. http://dx.doi.org/10.1053/j.jvca.2020.11.057. Epub 2020 Nov 28. PMID: 33298370; PMCID: PMC7698829.

20. European Medicines Agency. Tocilizumab (RoActemra) 20 mg/mL concentrate solution for infusion/162 mg solution for injection in pre-filled syringe: summary of product characteristics; 2016. Available from: http://www.ema.europa.eu [Accessed 13 April 2021].

21. Genentech Inc. Actemra (tocilizumab): US prescribing information; 2017. Available from: https://www.gene.com/download/pdf/actemra_prescribing.pdf [Accessed 13 April 2021].

22. Lesley J, Scott tocilizumab: a review in rheumatoid arthritis drugs. 2017; 77: 1865–79.

23. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020, ciaa954.

24. Tleyjeh IM, Kashour Z, Damaj M, Riazi M, Tlayjeh H, Altannir M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2020. S1198-1743(20)30690-X.

25. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with COVID-19 pneumonia. N Engl J Med. 2021;384:20–30. http://dx.doi.org/10.1056/NEJMoa2030340.

26. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bha-gani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021. http://dx.doi.org/10.1056/NEJMoa2028700. NEJMoa2028700.

27. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:24–31.

28. Hermine O, Mariette X, Tharaux P-L, Resche-Rigon M, Porcher R, Rayaud P, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:32–40.

29. RECOVERY Collaborative Group, Horby PW, Pessoa-Amorim G, Peto L, Brightling CE et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial | medRxiv [Internet]. Available from: https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1.full [Accessed 17 February 2021].

30. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19 – preliminary report [Internet]. Intensive Care Crit Care Med. 2021 [Accessed 1 February 2021].

31. Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ [Internet]. 2021:n84. Available from: https://www.bmj.com/lookup/doi/10.1136/bmj.n84 [Accessed 1 February 2021].
care unit: a multicentre observational study. Lancet Rheumatol. 2020;2:e603–12.
35. Guaraldi G, Meschìari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Septicemia in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2:e474–84.
36. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandez AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333–44.
37. Rossotti R, Travi G, Ughi N, Corradin M, Baiguera C, Fumagalli R, et al. Safety and efficacy of anti-IL-6 receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Infect. 2020;81:e11–7.
38. Rojas-Marté G, Khalid M, Mukhtar O, Hashmi AT, Waheed MA, Ehrlich S, et al. Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case-controlled study. QJM. 2020;113:546–50.
39. Bari SF, Khan A, Lawson T. C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. BMJ Case Rep. 2013;31:2013.
40. Palomar M, Álvarez-Lerma F, Riera A, Diaz MT, Torres F, Agra Y, Bacteremia Zero Working Group, et al. Impact of a national multimodal intervention to prevent cather-related bloodstream infection in the ICU: the Spanish experience. Crit Care Med. 2013;41:2364–72.
41. Álvarez-Lerma F, Palomar-Martínez M, Sánchez-García M, Martínez-Alonso M, Álvarez-Rodríguez J, Lorente L, et al. Prevention of ventilator-associated pneumonia: the multimodal approach of the Spanish ICU ‘pneumonia zero’ program. Crit Care Med. 2018;46:181–8.
42. Grupo de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS). Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). Informe del registro ENVIN; 2019. Available from: https://www.hvs.vehbron.net/envin-helics/ [Accessed 15 February 2021].
43. Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). Indicadores de Calidad en el enfermo crítico. Actualización; 2017. Available from: https://www.semicyuc.org/wpcontent/uploads/2018/10/indicadoresdecalidad2017_semicyuc-spa.pdf [Accessed 15 February 2021].
44. Soriano MC, Vaquero C, Ortiz-Fernández A, Caballero A, Blandino-Ortiz A, de Pablo R. Low incidence of co-infection, but high incidence of ICU-acquired infections in critically ill patients with COVID-19. J Infect. 2021;82:e20–1. http://dx.doi.org/10.1016/j.jinf.2020.09.010. Epub 2020 Sep 19. PMID: 32956729; PMCID: PMC7501527.
45. Nebreda-Mayoral T, Miguel-Gómez MA, March-Rosselló GA, Puente-Fuertes L, Cantón-Benito E, Martínez-García AM, et al. Enferm Infecc Microbiol Clin. 2020. http://dx.doi.org/10.1016/j.eimc.2020.11.003. S0213-005X(20)30404-3. English. Spanish. Epub ahead of print. PMID: 33413990; PMCID: PMC7713607.
46. Ramirez P, Gordón M, Martín-Cerezuella M, Villarreal E, Sancho E, Padrós M, et al. Acute respiratory distress syndrome due to COVID-19. Clinical and prognostic features from a medical Critical Care Unit in Valencia, Spain. Med Intensiva. 2021;45:27–34. http://dx.doi.org/10.1016/j.medin.2020.06.015. Epub 2020 Jul 11. PMID: 32919796; PMCID: PMC7836701.
47. Rodríguez A, Moreno G, Gómez J, Carbonell R, Picó-Plana E, Benavent Bofill C, et al. Severe infection due to the SARS-CoV-2 coronavirus: experience of a tertiary hospital with COVID-19 patients during the 2020 pandemic. Med Intensiva. 2020;44:525–33. http://dx.doi.org/10.1016/j.medin.2020.05.018. English. Spanish. Epub 2020 Jun 19. PMID: 32654921; PMCID: PMC7303662.
48. Bardí T, Pintado V, Gomez-Rojo M, Escudero-Sanchez R, Azzam Lopez A, Diez-Remesal Y, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. Eur J Clin Microbiol Infect Dis. 2021;40:495–502. http://dx.doi.org/10.1007/s10096-020-04142-w. Epub 2021 Jan 3. PMID: 33389263; PMCID: PMC7778834.
49. Consejo Asesor del Programa de Seguridad de Pacientes Críticos. Octubre 2020. Adaptación en la UCI de las recomendaciones de los Proyectos Zero durante la pandemia por SARS-CoV-2. Web del Ministerio de Sanidad, sección. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/ADAPTACION_EN_LA_UCI_DE_LAS_RECOMENDACIONES_DE_LOS_PROYECTOS_ZERO-COVID19-V1.pdf [Accessed 1 April 2021].
50. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect. 2020;26:1395–9. http://dx.doi.org/10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27. PMID: 32603803; PMCID: PMC7320692.
51. Menéndez R, Torres A. Treatment failure in community-acquired pneumonia. Chest. 2007;132:1348–55. http://dx.doi.org/10.1378/chest.06-1995. PMID: 17934120.
52. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200:e45–67. http://dx.doi.org/10.1164/rccm.201908-15815T. PMID: 31573350; PMCID: PMC6812437.
53. Schuettz P, Muller B, Christ-Crain M, Stolz D, Tamn M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012. CD007498.
54. Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174:84–93.
55. Langford BJ, So M, Raybardash S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622–9. http://dx.doi.org/10.1016/j.cmi.2020.07.016. 
56. Martin-Loeches I, Povoa P, Rodríguez A, Curcio D, Suarez D, Mira JP, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): a multicentre, prospective, observational study. Lancet Respir Med. 2015;3:859–68. http://dx.doi.org/10.1016/S2216-2600(15)00332.
57. Bloncz G, Kouatchet A, Chudeau N, Pontis E, Lorber J, Lemeur A, et al. Epidemiology and microbiology of ventilator-associated pneumonia in COVID-19 patients: a multicenter retrospective study in 188 patients in an uninfuned French region. Crit Care. 2021;25:72. http://dx.doi.org/10.1186/s13054-021-03493-w. PMID: 33602296.
58. Forel J-M, Voillet F, Pulina D, Gacouin A, Perrin G, Barrau K, et al. Ventilator-associated pneumonia and ICU mortality in severe ARDS patients ventilated according to a lung protective strategy. Crit Care. 2012;16:R65. http://dx.doi.org/10.1186/cc1113.12.
59. Chastre J, Fagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867–903. http://dx.doi.org/10.1164/ajrccm.165.7.2105078.
60. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, et al. Characterization and clinical course of 1000 patients with COVID-19 in New York: retrospective case series. medRxiv Prepr Serv Heal Sci. 2020. http://dx.doi.org/10.1101/2020.04.20.20072116.
61. Wu C, Chen X, Cai Y, Xia J, Zhou X, Su S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease
2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020, http://dx.doi.org/10.1001/jamainternmed.2020.0994.
62. Soriano MC, Vaqueró C, Ortiz-Fernández A, Caballero A, Blandino-Ortiz A, de Pablo R. Low incidence of COVID-19 in critically ill patients with COVID-19. J Infect. 2020, http://dx.doi.org/10.1016/j.jinf.2020.09.010. S0163-4453(20)30594-30596. Epub ahead of print. PMID: PMCID: PMC7501527.
63. Barrasa H, Martín A, Maynar J, Rello J, Fernández-Torres M, Aguirre-quiñonero A, et al. Alava COVID-19 Study Investigators. High rate of infections during ICU admission of patients with severe SARS-CoV-2 pneumonia: a matter of time? J Infect. 2020, http://dx.doi.org/10.1016/j.jinf.2020.12.001. S0163-4453(20)30761-1. Epub ahead of print. PMID: 33285217.
64. Rouze A, Martín-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med. 2021;47:188–98. https://doi.org/10.1007/s00134-020-06323-9. Epub 2021 Jan 3. PMID: 33388794; PMCID: PMC7778569.
65. Zaragoza R, Vidal-Cortés P, Aguilar G, Borges M, Díaz E, Ferrer R, et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care. 2020;24:383. https://doi.org/10.1186/s13054-020-03091-2. PMID: 32600375; PMCID: PMC7322703.
66. Engsbro AL, Israelen SB, Pedersen M, Tingsgaard S, Lisby G, Andersen CØ, et al. Predominance of hospital-acquired bloodstream infection in patients with Covid-19 pneumonia. Infect Dis (Lond). 2020;52:919–22.
67. Giacobbe DR, Battaglini D, Ball L, Brunetti I, Bruzzzone B, Codda G, et al. Bloodstream infections in critically ill patients with COVID-19. Eur J Clin Investig [Internet]. 2020;50:e13319. Available from: http://onlinelibrary.wiley.com/doi/abs/10.1111/eci.13319 [Accessed 13 November 2020].
68. Buetti N, Ruckly S, de Montmollin E, Reigner J, Terzi N, Cohen Y, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med. 2021;47:180–7.
69. Chaves F, Garnacho-Montero J, Del Pozo JL, Bouza E, Capdevila JA, de Cueto M, et al. Diagnosis and treatment of catheter-related bloodstream infection: clinical guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology and (SEIMC) and the Spanish Society of Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICUTJC). Med Intensiva. 2018;42:5–36.
70. Proyecto: “Prevención de la infección urinaria relacionada con sondas urétal en pacientes críticos ingresados en las unidades de cuidados intensivos” – ITU-ZERO. (seguridaddel paciente.es). Available from: //www.seguridaddelpaciente.es/resources/documentos/2018/04/02/ituzero/definitivo/PROYECTO-ITU-ZERO-2018-2020.pdf [Accessed 1 February 2021].
71. European Centre for Disease Prevention and Control. European surveillance of healthcare-associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Available from: http://ecdc.europa.eu/en/european-survey-healthcare-associated-infections-intensive-care-units-hainet-icu-protocol [Accessed 1 February 2021].
72. De Waale JJ, Martín-Loeches I. Optimal duration of antibiotic treatment in Gram-negative infections. Curr Opin Infect Dis. 2018;31:606–11, http://dx.doi.org/10.1097/QCO.0000000000000491. PMID: 30382951.
73. Jouan Y, Guillou A, Gonzalez L, Perez Y, Boisseau C, Ehrmann S, et al. Phenotypical and functional alteration of unconventional T cells in severe COVID-19 patients. J Exp Med. 2020;217:e20200872, http://dx.doi.org/10.1084/jem.20200872. PMID: 32886755; PMCID: PMC7472174.
74. Schauwvlieghe AFAD, Rijnders BJA, Philips H, Verwijr R, Vanderbeke L, Van Tienen C, Dutch-Belgian Mycosis study group, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018;6:782–92, http://dx.doi.org/10.1016/S2213-2600(18)30274-1. Epub 2018 Jul 31. PMID: 30076119.
75. Marr KA, Platt A, Tornheim JA, Zhang SX, Datta K, Cardozo C, et al. Aspergillosis complicating severe coronavirus disease. Emerg Infect Dis. 2021, http://dx.doi.org/10.3201/eid2701.200286.
76. Baroletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L; PREDICO Study Group, et al. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: a prospective study. Clin Infect Dis. 2020;ciaa1065, http://dx.doi.org/10.1093/cid/ciaa1065.
77. Donnelly JP, Chen SC, Kaufman CA, Steinbach WJ, Badley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367–76, http://dx.doi.org/10.1093/cid/ciz1008. PMID: 31802123; PMCID: PMC7486838.
78. Blot SI, Taccone FS, van den Abeele AM, Bulp B, Meersseman W, Brusselaers N, AspICU Study Investigators, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64, http://dx.doi.org/10.1164/rcrm.201111-1978OC. Epub 2012 Apr 19. Erratum in: Am J Respir Crit Care Med. 2012;186:808. PMID: 22517788.79.
79. Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020;46:1524–35, http://dx.doi.org/10.1007/s00134-020-06091-6. Epub 2020 Jun 22. PMID: 32572532; PMCID: PMC7306567.
80. White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis. 2020;ciaa1298, http://dx.doi.org/10.1093/cid/ciaa1298.
81. Lass-Flohr C, Lo Cascio G, Nucci M, Camargo Dos Santos M, Colombo AL, Vossen M, et al. Respiratory specimen and the diagnostic accuracy of Aspergillus lateral flow assays (LFA-IMMY™): real-life data from a multicentre study. Clin Microbiol Infect. 2019;25:1563.e1–3, http://dx.doi.org/10.1016/j.cmi.2019.08.009. Epub 2019 Aug 22. PMID: 31445208.
82. Marr KA, Datta K, Mehta S, Ostrander DB, Rock M, Francis J, et al. Urine antigen detection as an aid to diagnose invasive Aspergillosis. Clin Infect Dis. 2018;67:1705–11, http://dx.doi.org/10.1093/cid/ciy326. PMID: 29684106; PMCID: PMC6233688.
83. Jenks JD, Hoenigl M. Treatment of Aspergillosis. J Fungi (Basel). 2018;4:98, http://dx.doi.org/10.3390/jof4030098. PMID: 30126229; PMCID: PMC6162797.
84. Escribano P, Rodríguez-Sánchez B, Díaz-García J, Martín-Gómez MT, Ibañez-Martínez E, Rodríguez-Mayo M, et al. ASPEIN study group. Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain. Clin Microbiol Infect. 2020, http://dx.doi.org/10.1016/j.cmi.2020.09.042. S1189-743X(20)30596-6. Epub ahead of print. PMID: 33010446.
85. Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECM/M/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2020, http://dx.doi.org/10.1016/S1473-3099(20)30847-1.
86. Chanques G, Jaber S. Treating HSV and CMV reactivations in critically ill patients who are not immunocompromised: con. Intensive Care Med. 2014;40:1950–3.

87. Hagel S, Scherag A, Schuierer L, Hoffmann R, Luyt CE, Pletz MW, et al. Effect of antiviral therapy on the outcomes of mechanically ventilated patients with herpes simplex virus detected in the respiratory tract: a systematic review and meta-analysis. Crit Care. 2020;24:584.

88. Le Balc’h P, Pinceaux K, Pronier C, Seguin P, Tadié JM, Reizine F. Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit Care. 2020;24:30, http://dx.doi.org/10.1186/s13054-020-03252-3. PMID: 32859241; PMCID: PMC7453668.

89. Xu R, Zhou Y, Cai L, Wang L, Han J, Yang X, et al. Co-reactivation of human herpesvirus alpha subfamily (HSV 1 and VZV) in critically ill patients with COVID-19. Br J Dermatol. 2020;183:1145–7.

90. Carll WC, Rady MY, Salomao MA, Patel B, Singh VP, Sen A. Cytomegalovirus hemorrhagic enterocolitis associated with severe infection with COVID-19. BMJ Open Gastroenterol. 2021;8:e000556, http://dx.doi.org/10.1136/bmjgast-2020-000556. PMID: 33436481; PMCID: PMC7804824.